Novo Nordisk to buy hypertension treatment from for $1.3 billion from KBP Biosciences
Novo Nordisk A/S NVO, +1.96% NOVO.B, +0.08% said Monday it will pay $1.3 billion to KBP Biosciences to buy ocedurenone for uncontrolled hypertension. Ocedurenone is a pill that also has potential a...
How weight loss drugs could impact stocks
Weight loss drugs, such as Novo Nordisk's (NVO) Ozempic and Wegovy, continue to grow in popularity. With many brand and retailer CEOs signaling the hit to snack food sales, how will these drugs imp...
1 Big Risk Facing Ozempic, Wegovy, and Other GLP-1 Weight-Loss Drugs
Ozempic and Wegovy have soared in popularity because of their ability to help people lose weight. Some recent reports, however, have described several potential side effects of concern.
Novo Nordisk Boosts Its Guidance on Demand for Its Weight-Loss Drugs, Again
Novo Nordisk (NVO) boosted its guidance for the second time in two months as demand soars for its diabetes treatments, Ozempic and Wegovy. American depositary receipts (ADRs) of Novo Nordisk rose c...
Novo Nordisk raises full-year sales guidance due to Ozempic
Novo Nordisk (NVO) shares are up on the last trading day of the week as the company raised its full-year sales and operating profit citing U.S. sales from GLP-1 drugs Wegovy and Ozempic. Yahoo Fina...
Why Novo Nordisk Stock Raced Higher Today
The Danish pharmaceutical developer updated its 2023 guidance. It raised its projected growth rates for both sales and operating profit.
Novo Nordisk Raises Sales Outlook on Soaring Demand for Ozempic and Wegovy
Novo Nordisk now expects 2023 sales growth of between 32% and 38%.
Novo Nordisk hikes outlook on soaring demand for Wegovy, Ozempic
Novo Nordisk's forecast only confirms the frenzy for Wegovy and Ozempic, which patients seek for their ability to help them lose significant weight over time.
Novo Nordisk ups guidance, sees higher sales of Ozempic
Novo Nordisk (NYSE:NVO)'s shares have jumped after it lifted annual guidance, predicting a boost from higher sales of its diabetes drug Ozempic in the US. Europe's most valuable company, after rece...
Novo Nordisk boosts sales and profit outlook, buoyed by Ozempic and Wegovy
Novo Nordisk NVO, +1.36% on Friday boosted its full-year 2023 profit and sales outlook, reflecting heightened expectations for Ozempic and Wegovy sales. The company now projects full-year sales gro...
Novo Nordisk raises outlook for full-year sales, operating profit
Novo Nordisk has raised the outlook for its full-year sales and operating profit, the Danish drugmaker said in a statement on Friday.
Novo Nordisk warns online offers of fake Ozempic, Wegovy are on the rise
Novo Nordisk on Thursday warned of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online as illegal traders seek to take advantage of their huge po...
Australia's CSL tanks as Novo Nordisk's kidney trial success stokes competition concerns
Shares of biotechnology firm CSL fell to a four-year low on Thursday, after rival Novo Nordisk's Ozempic drug showed early signs of success in delaying the progression of kidney disease in diabetes...
Novo Nordisk stock pops on Ozempic kidney trial success
Shares of Novo Nordisk (NVO) rose on Wednesday after the drugmaker announced it was stopping a trial because early results show its popular diabetes drug Ozempic was effective in treating failure. ...
Ozempic Study Shakes Up Market for Kidney and Insulin Treatments
American depositary receipts (ADRs) of Novo Nordisk (NOVO) jumped over 6% in early trading on Wednesday, while shares of kidney dialysis machine and insulin pump makers tumbled, after the drug make...
Related Companies